Literature DB >> 29377617

Peroxiredoxin 1, restraining cell migration and invasion, is involved in hepatocellular carcinoma recurrence.

Ying Fang1, Juan He1, Harry L A Janssen2, Jian Wu3, Ling Dong1, Xi Zhong Shen1,4.   

Abstract

OBJECTIVE: Hepatocellular carcinoma (HCC) is a high-burden disease. Peroxiredoxin 1 (PRDX1) is a member of the peroxiredoxin family of antioxidant enzymes. The aim of this study was to assess the value of PRDX1 for predicting HCC recurrence after curative resection and to explore the role of PRDX1 in HCC cell migration and invasion.
METHODS: Data of patients with HCC who had undergone complete resection between 2002 and 2006 were collected. Immunohistochemical detection of PRDX1 in HCC tissue and adjacent non-cancerous tissue was conducted. Kaplan-Meier survival estimate and log-rank test were used to assess the relationship between PRDX1 expression and prognostic significance. HCC cell migration and invasion together with the interaction between PRDX1 and ubiquitin C-terminal hydrolase 37 (UCH37) were studied in vitro.
RESULTS: PRDX1 was expressed at lower levels in HCC tissues than in adjacent non-cancerous tissues, and PRDX1 was found to be an independent risk factor for disease-free survival and overall survival. PRDX1 restrained cell migration and invasion in vitro. PRDX1 was found to interact with UCH37 to affect HCC cell migration and invasion.
CONCLUSION: PRDX1 restrains cell migration and invasion in HCC cell lines and that may be involved in a UCH37-relevant pathway, suggesting that PRDX1 may be a new marker for HCC recurrence after surgery.
© 2018 Chinese Medical Association Shanghai Branch, Chinese Society of Gastroenterology, Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.

Entities:  

Keywords:  UCH37; hepatocellular carcinoma; human PRDX1 protein; invasion; migration

Mesh:

Substances:

Year:  2018        PMID: 29377617     DOI: 10.1111/1751-2980.12580

Source DB:  PubMed          Journal:  J Dig Dis        ISSN: 1751-2972            Impact factor:   2.325


  8 in total

Review 1.  Research Progress of DUB Enzyme in Hepatocellular Carcinoma.

Authors:  Jie Zhao; Jinhui Guo; Yanan Wang; Qiancheng Ma; Yu Shi; Feng Cheng; Qiliang Lu; Wen Fu; Guangxiong Ouyang; Ji Zhang; Qiuran Xu; Xiaoge Hu
Journal:  Front Oncol       Date:  2022-06-27       Impact factor: 5.738

2.  Silencing of Xeroderma Pigmentosum Group D Gene Promotes Hepatoma Cell Growth by Reducing P53 Expression.

Authors:  Hao Ding; Zhili Wen; Guofang Sun
Journal:  Med Sci Monit       Date:  2018-11-09

3.  The Prognosis Of Peroxiredoxin Family In Breast Cancer.

Authors:  Gang Wang; Wan-Chao Zhong; Yi-Hui Bi; Si-Yue Tao; Hai Zhu; Hai-Xing Zhu; A-Man Xu
Journal:  Cancer Manag Res       Date:  2019-11-14       Impact factor: 3.989

Review 4.  Ubiquitin Carboxyl-Terminal Hydrolases and Human Malignancies: The Novel Prognostic and Therapeutic Implications for Head and Neck Cancer.

Authors:  Chao Rong; Ran Zhou; Shan Wan; Dan Su; Shou-Li Wang; Jochen Hess
Journal:  Front Oncol       Date:  2021-01-29       Impact factor: 6.244

5.  Expression and prognostic roles of PRDXs gene family in hepatocellular carcinoma.

Authors:  Mingxing Xu; Jianliang Xu; Dun Zhu; Rishun Su; Baoding Zhuang; Ruiyun Xu; Lingli Li; Shuxian Chen; Yunbiao Ling
Journal:  J Transl Med       Date:  2021-03-26       Impact factor: 5.531

6.  The Prognostic Role of Glutathione and Its Related Antioxidant Enzymes in the Recurrence of Hepatocellular Carcinoma.

Authors:  Yung-Fang Hsiao; Shao-Bin Cheng; Chia-Yu Lai; Hsiao-Tien Liu; Shih-Chien Huang; Yi-Chia Huang
Journal:  Nutrients       Date:  2021-11-14       Impact factor: 5.717

7.  Up-regulation of peroxiredoxin-1 promotes cell proliferation and metastasis and inhibits apoptosis in cervical cancer.

Authors:  Ermei Lu; Xiaoli Hu; Chunyu Pan; Jingjing Chen; Yichi Xu; Xueqiong Zhu
Journal:  J Cancer       Date:  2020-01-01       Impact factor: 4.478

8.  Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma.

Authors:  Junyu Huo; Liqun Wu; Yunjin Zang
Journal:  J Cell Mol Med       Date:  2020-12-09       Impact factor: 5.295

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.